 - Patients who have not undergone surgical castration must continue treatment with an luteinizing hormone-releasing hormone LHRH agonist. In those patients where, for some reason, the LHRH agonist has been discontinued prior to entry on the study, it should be reinstituted and disease progression must be documented. 